ArticleCurrent issues in molecular biology2026
Transcriptomics, Proteomics and Network Pharmacology Reveal the Mechanisms of Cantharidin-Induced Kidney Injury in Rats.
Article in Current issues in molecular biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Cantharidin (CTD), the principal active constituent of the traditional Chinese medicine (TCM) Mylabris, exhibits potent antitumor activity. However, its clinical application is limited by organ toxicity (especially nephrotoxicity), and the underlying mechanisms remain incompletely defined. This research endeavored to elucidate the nephrotoxic effects and molecular mechanisms of CTD in rats using serum biochemical assays, histopathological examinations, and a multi-omics strategy. CTD treatment significantly increased levels of urea nitrogen and creatinine and induced histopathological injury in the kidneys. Transcriptomics, proteomics, and network pharmacology integrated analysis have revealed 14 common targets, mainly involved in the glutathione metabolic pathway. Further verification showed that CTD markedly upregulated protein expression of glutaminase (GLS), while downregulating homogentisate 1,2-dioxygenase (HGD), glutamate-cysteine ligase catalytic subunit (GCLC), and regulatory subunit (GCLM), thereby suppressing the glutathione metabolic pathway and exacerbating kidney injury. Our results indicate that CTD induces oxidative stress and consequent nephrotoxicity by inhibiting the glutathione metabolic pathway, providing a mechanistic basis for optimizing clinical strategies to mitigate CTD-induced kidney injury.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.